Knight Therapeutics (KHTRF) announced that its Mexican affiliate, Grupo Biotoscana de Especialidad, received regulatory approval from COFEPRIS for TAVALISSE for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KHTRF:
- Knight Therapeutics price target lowered to C$7.50 from C$8 at Raymond James
- Knight Therapeutics price target lowered to C$6.25 from C$6.75 at Stifel
- Knight Therapeutics Reports Q3 2024 Financial Results
- Knight Therapeutics downgraded to Hold from Buy at Mackie Research Capital
- Knight Therapeutics reports Q3 EPS C$0.00 vs. C$0.09 last year